Clinical trials: Thyroid Associated Ophthalmopathies
Healthy Volunteers
A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants
The primary objective of this trial are to assess the pharmacokinetics (PK) of a single subcutaneous (SC) administration of teprotumumab high-concentration formula (HCF) in healthy adult non-Japanese and Japanese participants and…
- Trial name
- NCT06674941
- Testing
- Teprotumumab
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Amgen
Thyroid Eye Disease
Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease
Thyroid eye disease (TED) is an autoimmune disease that affects the eye area. The disease presents with a variety of physical findings, including bulging of the eyes (proptosis), upper and lower eyelid retraction, and…
- Trial name
- HALR (NCT01738243)
- Testing
- Hyaluronic Acid Gel injection, Saline injection
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- University of California, Los Angeles
Thyroid Associated Ophthalmopathies
Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter…
- Trial name
- NCT07152366
- Testing
- IBI311, Glucocorticoids
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Changzheng Hospital
Thyroid Eye Disease
Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.
This is a prospective study designed to evaluate the efficacy and safety of Teprotumumab N01 in patients with Thyroid Eye Disease (TED).
- Trial name
- NCT07423013
- Testing
- [18F]AlF-NOTA-FAPI-04PET/CT, 5.0-T high-resolution MRI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
Thyroid Eye Disease, Eyelid Diseases
Tamsulosin for Thyroid Lid Retraction
The purpose of this study is to examine the effect of using Tamsulosin for treatment of eyelid retraction as part of thyroid eye disease.
- Trial name
- NCT04359979
- Testing
- Tamsulosin
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
Graves' Ophthalmopathy
The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy
The relationship between the method of the treatment of hyperthyroidism due to Graves' disease and the course of Graves' ophthalmopathy is debated.
- Trial name
- NCT01056419
- Testing
- Total Thyroidectomy, Propylthiouracil
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Ankara University
Active Moderate to Severe Graves' Orbitopathy
Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients
This is a single-arm, prospective, open-label, Phase II study that explored the efficacy and safety of SHR-1314 in active moderate to severe Graves' Orbitopathy.
- Trial name
- NCT05394857
- Testing
- SHR-1314
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Graves´ Disease
Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)
AGO study - adjuvant treatment, with NSAID, of endocrine ophthalmopathy in Graves´ disease Background - Already at diagnosis of Graves disease approximately 98% of the patients have morphological changes of the retrobulbar tissue…
- Trial name
- aGO (NCT01458600)
- Testing
- Diclofenac, Methimazole, L-thyroxin
- Where
- 3 sites in Sweden
- Volunteers
- 65 people
- Sponsor
- Mikael Lantz
Thyroid Eye Disease
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses.
- Trial name
- NCT06401044
- Testing
- AMG 732
- Where
- 44 sites in United States, Australia and 10 more
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Amgen
Thyroid Associated Ophthalmopathy
A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy
This is an exploratory study of the efficacy and safety of IBI311, a modified anti-IGF-1R antibody, in patients with steroid-resistant, thyroid associated ophthalmopathy (TAO). This study includes two stages.
- Trial name
- NCT06269393
- Testing
- IBI311
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Peking University People's Hospital
Exophthalmos, Orbitopathy, Graves
Deep Lateral Wall Partial Rim-Sparing Orbital Decompression for Treatment of Thyroid-Related Orbitopathy
The described technique of DLW-PRS decompression for TRO using SONOPET(R) appears to be safe and effective, reducing the complications associated with decompressing the orbital floor and medial wall.
- Conditions
- Exophthalmos, Orbitopathy, Graves, Surgery
- Trial name
- NCT04025034
- Testing
- Orbital decompression with ultrasonic bone removal
- Volunteers
- 35 people
- Sponsor
- Hospital Universitario 12 de Octubre
Thyroid Eye Disease
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
This is a multicenter, randomized, open-label, active-controlled Phase IV clinical trial in participants with active thyroid eye disease (TED).
- Trial name
- NCT07265258
- Testing
- Teprotumumab N01, Methylprednisolone
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Thyroid-Associated Ophthalmopathy
Establishment of Multimodal-multiparametric Progressive Prediction Models for Thyroid Associated Ophthalmopathy
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter…
- Trial name
- NCT06585592
- Volunteers
- 500 people
- Sponsor
- Shanghai Changzheng Hospital
Graves Ophthalmopathy, Graves Disease
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
The aim of this study is to evaluate the effects of subantimicrobial dose doxycycline (50 mg/d), administered for 12 wk, for patients with active moderate-severe Graves' Orbitopathy (GO).
- Conditions
- Graves Ophthalmopathy, Graves Disease, Eye Diseases, Thyroid Diseases
- Trial name
- NCT01727973
- Testing
- Doxycycline
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Sun Yat-sen University
Thyroid Eye Disease
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease
This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with…
- Trial name
- UplighTED (NCT06307613)
- Testing
- Efgartigimod PH20 SC
- Where
- 77 sites in United States, Australia and 14 more
- Volunteers
- 102 people
- Sponsor
- argenx
Thyroid Eye Disease, TED, Graves Ophthalmopathy
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Thyroid Eye Disease (TED), also known as Graves' orbitopathy, is an autoimmune condition that causes inflammation and tissue expansion behind the eyes, leading to bulging eyes (proptosis), double vision, and pain.
- Conditions
- Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves Orbitopathy
- Trial name
- TOFA-GO (NCT07547930)
- Testing
- Tofacitinib
- Where
- China
- Volunteers
- 8 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Thyroid Eye Disease, Thyroid Eye Disease, TED
Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease
The goal of this interventional study is to compare the clinical outcomes of shortened 4-infusion course versus the standard 8-infusion course of Teprotumumab (Tepezza) in patients with active Thyroid Eye Disease (TED).
- Conditions
- Thyroid Eye Disease, Thyroid Eye Disease, TED, Thyroid Eye Disease (TED)
- Trial name
- NCT07308964
- Testing
- Teprotumumab Injection [Tepezza]
- Volunteers
- 40 people
- Sponsor
- Sheba Medical Center
Graves Ophthalmopathy
Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.
This study is a randomized, controlled, multi-center clinical study, the purpose is to evaluate the efficacy and safety of rapamycin combined with methylprednisolone in the treatment of moderate to severe active GO.
- Trial name
- NCT05532072
- Testing
- Rapamycin, Methylprednisolone
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Thyroid Eye Disease
A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease
This trial will evaluate the effects of Lu AG22515 in adult men and women with moderate-to-severe thyroid eye disease (TED). TED is an autoimmune condition closely related to Graves' Disease.
- Trial name
- NCT06557850
- Testing
- Lu AG22515
- Where
- 6 sites in Bosnia and Herzegovina, Bulgaria and 1 more
- Volunteers
- 20 people
- Sponsor
- H. Lundbeck A/S
Thyroid Eye Disease (TED), Graves Ophthalmopathy
Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE)
This prospective observational study evaluates the feasibility and clinical utility of a smartphone-based artificial intelligence (AI) self-monitoring system in adults with thyroid eye disease (TED) undergoing non-surgical…
- Conditions
- Thyroid Eye Disease (TED), Graves Ophthalmopathy, Thyroid Associated Ophthalmopathies
- Trial name
- THYROSCOPE-TED (NCT07623993)
- Testing
- Smartphone-based AI self-monitoring application (Glandy CAS/EXO/LID)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- THYROSCOPE INC.